Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study

BACKGROUND: Alemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses. The objective of this study was to describe the effectiveness and safety data of ALZ and to rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichau, Sara, López Ruiz, Rocío, Ruíz de Arcos, María, Ruiz-Peña, Juan Luis, Navarro, Guillermo, Calleja, Miguel Ángel, Moreno-Amador, José Luis, Dotor García-Soto, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044139/
https://www.ncbi.nlm.nih.gov/pubmed/36998778
http://dx.doi.org/10.3389/fneur.2023.1112193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044139/
https://www.ncbi.nlm.nih.gov/pubmed/36998778
http://dx.doi.org/10.3389/fneur.2023.1112193

Ejemplares similares